QQ客服 官方微博 反馈留言

浏览/检索结果: 共13条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文 PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 卷号: 11, 期号: 1 作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/04 Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文 The Patient - Patient-Centered Outcomes Research, 2018, 卷号: 11, 期号: 1, 页码: 131-141 作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11 作者:  Hirsh, V.;  Tan, E.;  Wu, Y.;  Sequist, L.;  Zhou, C. 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/04 dose adjustment  PROs  afatinib   EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 期刊论文 BRITISH JOURNAL OF CANCER, 2017, 卷号: 116, 期号: 2 作者:  Wu, Yi-Long;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 afatinib  circulating cell-free DNA  ErbB family blocker  EGFR mutation  non-small cell lung cancer   Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial 期刊论文 2017, 卷号: 28, 期号: 2, 页码: 270-277 作者:  Paz-Ares, L.;  Tan, E.H.;  O'Byrne, K.;  Zhang, L.;  Hirsh, V. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 afatinib  gefitinib  NSCLC  overall survival   Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) 期刊论文 2017, 卷号: 72, 页码: S184-S184 作者:  Hirsh, V.;  Park, K.;  Tan, E. H.;  Zhang, L.;  O'Byrne, K. 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/04 Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) 会议论文 EUROPEAN JOURNAL OF CANCER, 2017-02-01 作者:  Hirsh, V.;  Park, K.;  Tan, E. H.;  Zhang, L.;  O'Byrne, K. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials 期刊论文 ANNALS OF ONCOLOGY, 2016, 卷号: 27, 期号: 11 作者:  Zhou, C.;  Yang, J. C. -H.;  Sequist, L. V.;  Schuler, M.;  Geater, S. L. 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/04 afatinib  NSCLC  EGFR  first-line  phase III  dose   Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials 期刊论文 Annals of Oncology, 2016, 卷号: 27, 期号: 11, 页码: 2103-2110 作者:  Yang, J. C. -H.;  Sequist, L. V.;  Zhou, C.;  Schuler, M.;  Geater, S. L. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/03 adverse event  epidermal growth factor receptors  mutation  plasma drug concentration   Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) 期刊论文 2016, 卷号: 27 作者:  Paz-Ares, L.;  Tan, E. H.;  Zhang, L.;  Hirsh, V.;  O'Byrne, K. 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04